WHAT THE STUDY ACTUALLY SAYS

Two antibodies held HIV in check every eight weeks in an early-stage trial

In a phase 1b/2a study, 20 adults stopped their daily HIV pills and switched to an eight-weekly antibody infusion; most stayed virally suppressed at 24 weeks. It is a small, early trial.

A combination of two long-acting antibodies, infused once every eight weeks, kept HIV suppressed in most of a small group of adults who stopped their daily antiretroviral pills, in an early-stage trial published in The Lancet HIV [s1]. The result is a proof of concept, not a treatment: it involved 20 people over 24 weeks, with no comparison group. But it points at a goal the field has pursued for years — replacing lifelong daily tablets with an occasional injection or infusion.

Why antibodies, and why this matters

Modern HIV treatment is highly effective but demands daily pills, indefinitely. Long-acting options reduce that burden, and antibody-based regimens are one route being explored. The two drugs here work in different ways: TMB-365 is a monoclonal antibody directed at the CD4 receptor, and TMB-380 is a long-acting broadly neutralising antibody that targets the CD4-binding site on gp120, a protein on the virus's surface [s1]. The trial tested whether the pair, given together, is safe and can hold the virus down on its own.

What the trial did

This was a phase 1b/2a, open-label, dose-escalation study in virologically suppressed adults aged 18 to 70 who were living with HIV and on stable oral combination antiretroviral therapy, enrolled from six clinics in California, Florida and Texas [s1]. It ran in two parts. In phase 1b, participants received a single intravenous dose of TMB-365 plus TMB-380 at 2,400 mg, 3,200 mg or 4,800 mg and stayed on their usual pills for 12 to 16 weeks, so the antibodies could be assessed for safety and blood levels without putting anyone at risk [s1]. In phase 2a, participants stopped their antiretroviral therapy at the start and received 4,800 mg of each antibody intravenously every eight weeks, three times over 24 weeks, with no pre-treatment screening for resistance [s1]. The trial is registered as NCT05275998 [s2].

Between 5 July 2022 and 20 November 2024, 30 participants (28 male, two female) were enrolled in phase 1b and 20 male participants in phase 2a [s1]. In the phase 2a group, two participants discontinued early and one was lost to follow-up [s1].

What it found

On safety, the regimen was clean: no serious adverse events and none of grade 3 or worse were observed, and all treatment-emergent side effects were mild or moderate [s1]. The pharmacokinetic targets — the blood levels the antibodies needed to reach — were met at week 8 in the phase 1b 4,800 mg group [s1].

The headline came from phase 2a, where people were relying on the antibodies alone. At week 24, viral suppression was maintained in 16 of 17 participants (94%, 95% CI 71 to 100) in the per-protocol analysis, and in 16 of 20 (80%, 95% CI 56 to 94) when everyone who started was counted [s1]. No confirmed virological failures were reported [s1]. The authors conclude that the 4,800 mg combination every eight weeks appears safe, might work as maintenance therapy in people whose virus is already suppressed, and merits further study [s1].

How to read it

The caveats are the size and shape of the trial, not the numerals. Twenty people took the antibodies alone, and the two ways of counting them produce quite different numbers — 94% among those who completed per protocol, but 80% once early dropouts are included, because three of twenty did not finish as planned. Both estimates carry wide confidence intervals, so the true maintenance rate could be considerably lower than the point estimate. There was no comparison group continuing standard pills, the study was open-label (everyone knew what they were getting), it enrolled almost entirely men, and 24 weeks is a short window against the lifelong horizon of HIV treatment. It was also funded by the antibodies' developer, TaiMed Biologics [s1].

Crucially, this was maintenance in people already suppressed on conventional therapy — not a test of whether the antibodies can bring an untreated infection under control, which is a different and harder question. And giving the antibodies without screening for pre-existing resistance is a design choice a larger trial will have to scrutinise.

What to watch

The next steps are a controlled trial large enough to estimate the failure rate reliably, longer follow-up to see whether suppression holds beyond 24 weeks, and data in women and in more diverse participants. Whether an eight-weekly infusion is practical enough to compete with existing long-acting injectables is a separate question this study does not settle. For now, the honest summary is that two antibodies kept HIV down in most of a small, early group — an encouraging signal that needs a bigger trial to mean anything for patients [s1].

This article describes clinical-trial results and is not medical advice. Anyone living with HIV should make treatment decisions with their own clinician and should never stop antiretroviral therapy on their own.

Sources

  1. Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study — The Lancet HIV , November 10, 2026
  2. A Study of TMB-365 in Combination With TMB-380 in Virologically Suppressed Adults With HIV-1 (NCT05275998) — ClinicalTrials.gov

More on

Related coverage